Corona Remedies' cash efficiency is robust, with an OCF to EBITDA ratio of 87%, suggesting they're effectively converting earnings into cash. The company hints at potential growth through more acquisitions, backed by their impressive financial statistics.

Corona Remedies anticipates significant growth of 20-25% annually for its product Wokadine within the next three years, setting ambitious expansion plans in motion.

Corona Remedies concludes 2022 with a cash reserve of INR 112 crores. The company aims to achieve a compound annual growth rate (CAGR) of 20-25% for its product Wpladone over the next three years.

Corona Remedies has purchased Wokadine from Dr. Reddy's, bolstering its position as the second player in India's Povidone Iodine market worth approximately 6.5 billion INR. The acquisition is self-funded using internal cash reserves.